Viatris Opens $36.50 Tender for Pacira BioSciences, Clock Now Running

Viatris formally commenced its tender offer for all outstanding shares of Pacira BioSciences at $36.50 per share in cash. The offer period is now open, triggering Hart-Scott-Rodino antitrust filing deadlines and setting the calendar for what Viatris is positioning as a clean, single-product consolidation in the injectable pain-management category. Pacira closed Friday at $35.82, implying a 1.9% spread to the offer price and signaling modest arbitrage confidence in deal completion.

Pacira's core asset is Exparel, a long-acting local anesthetic generating roughly $540 million in trailing revenue. Viatris, with $16.1 billion in 2023 sales, sees the acquisition as a bolt-on to its existing pain and anesthesia portfolio, particularly in hospital and ambulatory surgery settings where Exparel has established formulary penetration. The deal values Pacira's equity at approximately $2.1 billion, or roughly 3.9x trailing revenue, a discount to the 4.5x median for specialty pharma M&A over the past eighteen months. That discount reflects Exparel's patent exposure—key composition-of-matter patents expire in 2031, with formulation patents extending to 2034, leaving Viatris roughly seven years of exclusivity runway before generic erosion begins.

The timing matters because Viatris is executing this tender without board approval from Pacira, though the absence of a poison pill simplifies execution. Pacira's management has been publicly silent since Viatris disclosed its offer in mid-January, and the lack of a competing bidder or formal rejection suggests either quiet board negotiation or resigned acceptance of the premium over Pacira's pre-announcement trading range of $28 to $31. The tender structure, rather than a negotiated merger, allows Viatris to move quickly—offers typically close within 20 to 60 business days if antitrust clearance arrives on schedule. The FTC's recent focus on pharmaceutical consolidation adds procedural risk, but Exparel's niche indication and Viatris's limited overlap in injectables reduce the likelihood of a Second Request.

For allocators, the arbitrage spread is narrow enough to signal that event-driven funds see minimal regulatory or financing risk. Viatris carries $21.8 billion in net debt as of Q3 2024, but the company generates over $4 billion in annual EBITDA, leaving room for a $2.1 billion cash acquisition without triggering covenant issues or materially altering leverage ratios. The narrow spread also suggests limited expectation of a topping bid—Pacira's shareholder base is largely institutional, with Vanguard and BlackRock holding combined stakes above 20%, and neither has filed a 13D objecting to the offer price.

Operators should watch three near-term catalysts: HSR clearance, expected within 30 to 45 days absent a Second Request; Pacira's formal board response, due within 10 business days of the offer commencement under SEC rules; and any amendments to the tender terms if Viatris faces unexpected shareholder resistance. The offer includes a standard 90% minimum tender condition, meaning Viatris can walk if insufficient shares are tendered, though the current spread pricing suggests the market assigns that scenario low probability.

The deal closes a chapter on Pacira as a standalone specialty pharma and confirms Viatris's strategy of acquiring durable, off-patent-runway assets to offset erosion in its legacy generic base. Exparel's 2031 patent cliff will arrive just as Viatris's current portfolio faces its own biosimilar pressures, making the acquisition a medium-term revenue plug rather than a transformational repositioning. The narrow spread and swift commencement suggest the market has already priced in completion, leaving little edge for late-arriving arbitrageurs.